Ghent University Academic Bibliography

Your filters: cql: author="Kley, Niko" or (type any "bookEditor issueEditor" and editor="Kley, Niko")

Add to list
- Journal Article
- A1
- open access
High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphoma

Willem Daneels (UGent) , Alexander Van Parys (UGent) , Leander Huyghe (UGent) , Elke Rogge (UGent) , Steffi De Rouck (UGent) , Ruben Christiaen, Lennart Zabeau (UGent) , Sylvie Taveirne (UGent) , Jo Van Dorpe (UGent) , Niko Kley, et al.

(2024) EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 13(1).
Add to list
- Journal Article
- A1
- open access
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state

Sandra Van Lint (UGent) , Alexander Van Parys (UGent) , Bram Van Den Eeckhout (UGent) , Niels Vandamme (UGent) , Stephane Plaisance, Annick Verhee (UGent) , Dominiek Catteeuw (UGent) , Elke Rogge (UGent) , Jennifer De Geest (UGent) , Nele Vanderroost (UGent) , et al.

(2023) MOLECULAR CANCER. 22(1).
Add to list
- Journal Article
- A1
- open access
Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE

Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Elke Rogge, Annick Verhee (UGent) , Bram Van Den Eeckhout (UGent) , Shengru Pang, Marco Prinz, Niko Kley, Gilles Uze and Jan Tavernier (UGent)

(2021) SCIENTIFIC REPORTS. 11(1).
Add to list
- Journal Article
- A1
- open access
Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication

Bram Van Den Eeckhout (UGent) , Leander Huyghe (UGent) , Sandra Van Lint (UGent) , Elianne Burg (UGent) , Stéphane Plaisance, Frank Peelman (UGent) , Anje Cauwels (UGent) , Gilles Uzé, Niko Kley, Sarah Gerlo (UGent) , et al.

(2021) JOURNAL FOR IMMUNOTHERAPY OF CANCER. 9(11).
Add to list
- Journal Article
- A1
- open access
Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant

Bram Van Den Eeckhout (UGent) , Lien Van Hoecke (UGent) , Elianne Burg (UGent) , Sandra Van Lint (UGent) , Frank Peelman (UGent) , Niko Kley, Gilles Uzé, Xavier Saelens (UGent) , Jan Tavernier (UGent) and Sarah Gerlo (UGent)

(2020) NPJ VACCINES. 5(1).
Add to list
- Conference Paper
- C3
Selected IL-1 activity on CD8+ T cells allows for safe enhancement of cellular immune responses

Bram Van Den Eeckhout (UGent) , Lien Van Hoecke (UGent) , Elianne Burg (UGent) , Sandra Van Lint (UGent) , Frank Peelman (UGent) , Niko Kley, Gilles Uzé, Xavier Saelens (UGent) , Jan Tavernier (UGent) and Sarah Gerlo (UGent)

(2020) T Cell Memory, Abstracts.
Add to list
- Journal Article
- A1
- open access
Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies

Leander Huyghe (UGent) , Alexander Van Parys (UGent) , Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Stijn De Munter (UGent) , Jennyfer Bultinck (UGent) , Lennart Zabeau (UGent) , Jeroen Hostens, An Goethals, Nele Vanderroost (UGent) , et al.

(2020) EMBO MOLECULAR MEDICINE. 12(2).
Add to list
Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice

Anje Cauwels (UGent) , Sandra Van Lint (UGent) , Dominiek Catteeuw (UGent) , Shengru Pang, Franciane Paul, Elke Rogge (UGent) , Annick Verhee (UGent) , Marco Prinz, Niko Kley, Gilles Uzé, et al.

(2019) JOURNAL OF AUTOIMMUNITY. 97. p.70-76
Add to list
The use of mammalian two-hybrid technologies for high-throughput drug screening

Sam Lievens (UGent) , Maureen Caligiuri, Niko Kley and Jan Tavernier (UGent)

(2012) METHODS. 58(4). p.335-342

Academic Bibliography

High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphoma

A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state

Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE

Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication

Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant

Selected IL-1 activity on CD8+ T cells allows for safe enhancement of cellular immune responses

Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies

Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice

The use of mammalian two-hybrid technologies for high-throughput drug screening

Contents

Support

Contact